Townsquare Capital LLC Has $6.90 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Townsquare Capital LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 13.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,127 shares of the pharmaceutical company's stock after buying an additional 2,073 shares during the period. Townsquare Capital LLC's holdings in Vertex Pharmaceuticals were worth $6,897,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock worth $9,366,113,000 after acquiring an additional 98,654 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Vertex Pharmaceuticals by 23.3% in the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock valued at $2,382,407,000 after purchasing an additional 1,117,214 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Vertex Pharmaceuticals by 23.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock worth $1,519,302,000 after purchasing an additional 704,575 shares during the last quarter. Norges Bank purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at $1,374,948,000. Finally, Edgewood Management LLC lifted its stake in Vertex Pharmaceuticals by 91.2% during the fourth quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company's stock worth $1,190,626,000 after purchasing an additional 1,410,238 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Up 0.7 %

Shares of VRTX stock traded up $3.21 during trading hours on Friday, hitting $489.10. 1,205,462 shares of the company were exchanged, compared to its average volume of 1,330,419. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock has a market capitalization of $125.60 billion, a price-to-earnings ratio of -222.32, a P/E/G ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The business's 50-day simple moving average is $486.76 and its two-hundred day simple moving average is $465.20.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 530 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares of the company's stock, valued at approximately $27,825,928.26. This trade represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

VRTX has been the topic of a number of research analyst reports. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and raised their price objective for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target on the stock. in a research note on Thursday, January 30th. Piper Sandler decreased their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, Royal Bank of Canada lifted their target price on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a report on Tuesday, April 1st. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $512.41.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.